Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
HSAQ Stock Summary
In the News
Health Sciences Acquisitions Corporation 2 Announces Closing of Upsized $160 Million Initial Public Offering, Including Full Exercise of the Underwriters' Over-Allotment Option
Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ, the "Company" or "HSAC 2") announced today that it closed its initial public offering of 16,000,000 ordinary shares, which included the full exercise of the underwriters' over-allotment option. The ordinary shares were sold at $10.00 per ordinary share, resulting in total gross proceeds of $160,000,000.
HSAQ Financial details
HSAQ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|
2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | |
Net income per share | -0.01 | -0.02 | -0.15 | |
Operating cash flow per share | -0.01 | -0.01 | -0.1 | |
Free cash flow per share | -0.01 | -0.01 | -0.1 | |
Cash per share | 7.99 | 0.09 | 4.14 | |
Book value per share | 7.72 | -0.19 | -0.42 | |
Tangible book value per share | 7.72 | 7.7 | 3.7 | |
Share holders equity per share | 7.72 | -0.19 | -0.42 | |
Interest debt per share | 0 | 0 | -0.02 | |
Market cap | 259.71M | 204.36M | 163.93M | |
Enterprise value | 257.68M | 202.61M | 163.75M | |
P/E ratio | -1.5K | -563.37 | -68.59 | |
Price to sales ratio | 0 | 0 | 0 | |
POCF ratio | -1K | -750.33 | -103.8 | |
PFCF ratio | -1K | -750.33 | -103.8 | |
P/B Ratio | 1.66 | -51.84 | -23.61 | |
PTB ratio | 1.66 | -51.84 | -23.61 | |
EV to sales | 0 | 0 | 0 | |
Enterprise value over EBITDA | -1.48K | -534.93 | -59.87 | |
EV to operating cash flow | -996.8 | -743.89 | -103.69 | |
EV to free cash flow | -996.8 | -743.89 | -103.69 | |
Earnings yield | 0 | 0 | -0.01 | |
Free cash flow yield | 0 | 0 | -0.01 | |
Debt to equity | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | |
Net debt to EBITDA | 11.68 | 4.63 | 0.06 | |
Current ratio | 18.07 | 10.88 | 0.17 | |
Interest coverage | 0 | 24.67 | 8.92 | |
Income quality | 1.49 | 0.72 | 0.58 | |
Dividend Yield | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | |
Graham number | 1.22 | 0.28 | 1.18 | |
ROIC | 0 | 0.1 | 0.39 | |
Return on tangible assets | 0 | 0 | -0.04 | |
Graham Net | 7.71 | -0.2 | 3.69 | |
Working capital | 2.03M | 1.64M | -1.44M | |
Tangible asset value | 156.44M | 156.06M | 60.73M | |
Net current asset value | -3.57M | -3.96M | -7.04M | |
Invested capital | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | |
Average payables | 0 | 7.6K | 189.16K | |
Average inventory | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | |
ROE | 0 | 0.09 | 0.34 | |
Capex per share | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.03 | -0.08 | 0 | 0 | 0 | |
Operating cash flow per share | -0.04 | -0.03 | 0 | 0 | 0 | |
Free cash flow per share | -0.04 | -0.03 | 0 | 0 | 0 | |
Cash per share | 4.99 | 4.14 | 0 | 0 | 0 | |
Book value per share | 4.49 | -0.42 | 0 | 0 | 0 | |
Tangible book value per share | 4.49 | 3.7 | 0 | 0 | 0 | |
Share holders equity per share | 4.49 | -0.42 | 0 | 0 | 0 | |
Interest debt per share | 0.01 | -0.01 | 0 | 0 | 0 | |
Market cap | 135.85M | 163.93M | 367.94B | 460.71B | 469.09B | |
Enterprise value | 135.12M | 163.75M | 367.92B | 460.69B | 469.08B | |
P/E ratio | -78.88 | -30.05 | -9.73K | -9.56K | -8.81K | |
Price to sales ratio | 0 | 0 | 316.1K | 503.5K | 1.12M | |
POCF ratio | -237.72 | -292.7 | -25.58K | 0 | 0 | |
PFCF ratio | -237.72 | -292.7 | -25.52K | 0 | 0 | |
P/B Ratio | 2.21 | -23.61 | 3.69K | 5.15K | 5.89K | |
PTB ratio | 2.21 | -23.61 | 3.69K | 5.15K | 5.89K | |
EV to sales | 0 | 0 | 316.08K | 503.49K | 1.12M | |
Enterprise value over EBITDA | -242.07 | -186.78 | -31.87K | -35.56K | -32.3K | |
EV to operating cash flow | -236.43 | -292.39 | -25.58K | 0 | 0 | |
EV to free cash flow | -236.43 | -292.39 | -25.52K | 0 | 0 | |
Earnings yield | 0 | -0.01 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 0.02 | 0.02 | 0.14 | |
Debt to assets | 0 | 0 | 0.02 | 0.02 | 0.1 | |
Net debt to EBITDA | 1.32 | 0.2 | 1.43 | 1.11 | 0.52 | |
Current ratio | 0.61 | 0.17 | 10.77 | 10.08 | 5.13 | |
Interest coverage | -6.37 | 2.75 | -11.36 | -13.77 | -15.87 | |
Income quality | 0.83 | 0.64 | 1.31 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 7.09 | 9.29 | 20.42 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | -0.03 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -0.49 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 1.28 | 0 | 0 | |
Graham number | 1.78 | 0.89 | 0.01 | 0 | 0 | |
ROIC | -0.01 | 0.09 | -0.08 | -0.14 | -0.16 | |
Return on tangible assets | -0.01 | -0.02 | -0.07 | -0.1 | -0.11 | |
Graham Net | 4.48 | 3.69 | 0 | 0 | 0 | |
Working capital | -567.95K | -1.44M | 117.82M | 107.73M | 88.72M | |
Tangible asset value | 61.61M | 60.73M | 99.75M | 89.44M | 79.66M | |
Net current asset value | -6.17M | -7.04M | 93.35M | 83.15M | 73.49M | |
Invested capital | 0 | 0 | 0.02 | 0.02 | 0.14 | |
Average receivables | 0 | 0 | 38K | 123.5K | 128.5K | |
Average payables | 226.11K | 329.25K | 1.57M | 2.89M | 3.08M | |
Average inventory | 0 | 0 | 116K | 205K | 157.5K | |
Days sales outstanding | 0 | 0 | 5.88 | 16.82 | 18.47 | |
Days payables outstanding | 0 | 0 | 5.66K | 5.02K | 6.91K | |
Days of inventory on hand | 0 | 0 | 474.55 | 296.67 | 300.73 | |
Receivables turnover | 0 | 0 | 15.32 | 5.35 | 4.87 | |
Payables turnover | 0 | 0 | 0.02 | 0.02 | 0.01 | |
Inventory turnover | 0 | 0 | 0.19 | 0.3 | 0.3 | |
ROE | -0.01 | 0.2 | -0.09 | -0.13 | -0.17 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
HSAQ Frequently Asked Questions
What is Health Sciences Acquisitions Corporation 2 stock symbol ?
Health Sciences Acquisitions Corporation 2 is a US stock , located in New york of Ny and trading under the symbol HSAQ
What is Health Sciences Acquisitions Corporation 2 stock quote today ?
Health Sciences Acquisitions Corporation 2 stock price is $13.31 today.
Is Health Sciences Acquisitions Corporation 2 stock public?
Yes, Health Sciences Acquisitions Corporation 2 is a publicly traded company.